Rate My Professor James Lindsay

Professor James Lindsay, FRCP, PhD, BM BCh, is Professor of Inflammatory Bowel Disease at Barts and the London School of Medicine and Dentistry, Queen Mary University of London, within the Faculty of Medicine and Dentistry. He earned his BA in Medical Sciences from the University of Cambridge in 1990, BM BCh from the University of Oxford in 1993, PhD in mucosal immunology from Imperial College London in 2002, and became a Fellow of the Royal College of Physicians in 2008. Qualifying in medicine in 1993, he serves as a Consultant Gastroenterologist at Barts Health NHS Trust, where he leads the adolescent and adult inflammatory bowel disease (IBD) service at The Royal London Hospital alongside a full multidisciplinary team. He also directs the IBD module for the MSc in Gastroenterology at Queen Mary University of London since 2017 and maintains a private clinic at the London Digestive Centre with a dedicated IBD multidisciplinary discussion.

Professor Lindsay's research centers on translational mucosal immunology in IBD, encompassing leukocyte trafficking, monocyte and macrophage differentiation, and fibrosis control. He is Chief Investigator for multiple IBD clinical trials, including the NIHR-funded ASTIClite trial evaluating low-intensity autologous haematopoietic stem cell transplantation for refractory Crohn’s disease. His contributions include leadership on the British Society of Gastroenterology IBD Clinical Trials Steering Group. Previously, he held positions as Education Officer and Governing Board member of the European Crohn’s and Colitis Organisation (ECCO), ECCO e-learning ambassador, and chair of the ECCO Education Committee. He chaired ECCO working groups developing consensus guidelines on Crohn’s disease and ulcerative colitis management and is a member of the International Organisation of IBD (IOIBD). Key publications feature the 'UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care' (Gut, 2017), analyses of long-term safety of upadacitinib in IBD (Clinical Gastroenterology and Hepatology, 2026), and studies on stem cell transplantation efficacy in Crohn’s disease (JAMA, 2015), alongside extensive outputs in Journal of Crohn’s and Colitis and other premier journals.